Yu Yao

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

Yongliang Zhang, Yu Yao, Yaping Xu et al. · Nature Communications · 2021 · 291 citations · Full text

Medicine, Genetics, Oncology +12

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

RETRACTED ARTICLE: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway

Xiao Fu, Mengjie Liu, Shengyang Qu et al. · Journal of Experimental & Clinical Cancer Research · 2018 · 222 citations · Full text

Medicine, Oncology, Pharmacology +17

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li et al. · Journal of Clinical Oncology · 2022 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17